Clinical Trials
9 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06130826 2026-06-03
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Suspended
NCT04550494 2026-05-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05619016 2022-11-30
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
Karolinska University Hospital
Phase 2 Unknown
NCT00900302 2016-02-10
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
OHSU Knight Cancer Institute
Completed
NCT00369109 2013-04-08
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
Barbara Ann Karmanos Cancer Institute
Completed